Evidence that Formulations of the Selective MAO-B Inhibitor, Selegiline, which Bypass First-Pass Metabolism, also Inhibit MAO-A in the Human Brain

Selegiline (L-deprenyl) is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) at the conventional dose (10 mg/day oral) that is used in the treatment of Parkinson's disease. However, controlled studies have demonstrated antidepressant activity for high doses of oral selegiline a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuropsychopharmacology
Main Authors: Fowler, Joanna S, Logan, Jean, Volkow, Nora D, Shumay, Elena, McCall-Perez, Fred, Jayne, Millard, Wang, Gene-Jack, Alexoff, David L, Apelskog-Torres, Karen, Hubbard, Barbara, Carter, Pauline, King, Payton, Fahn, Stanley, Gilmor, Michelle, Telang, Frank, Shea, Colleen, Xu, Youwen, Muench, Lisa
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2015
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4289953/
https://ncbi.nlm.nih.gov/pubmed/25249059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/npp.2014.214
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados